PVCT Provectus Biopharmaceuticals Inc

Price (delayed)

$0.15

Market cap

$62.93M

P/E Ratio

N/A

Dividend/share

N/A

EPS

$0

Enterprise value

$64.67M

Highlights
The net income is up by 22% year-on-year but it has declined by 2% since the previous quarter
The gross profit has contracted by 29% from the previous quarter and by 27% YoY
The company's revenue fell by 29% QoQ and by 27% YoY

Key stats

What are the main financial stats of PVCT
Market
Shares outstanding
419.52M
Market cap
$62.93M
Enterprise value
$64.67M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
104.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
107.53
Earnings
Revenue
$601,437
EBIT
-$2.97M
EBITDA
-$2.91M
Free cash flow
-$2.77M
Per share
EPS
$0
Free cash flow per share
-$0.01
Book value per share
-$0.02
Revenue per share
$0
TBVPS
$0
Balance sheet
Total assets
$1.69M
Total liabilities
$9.21M
Debt
$3.16M
Equity
-$7.52M
Working capital
-$7.58M
Liquidity
Debt to equity
-0.42
Current ratio
0.17
Quick ratio
0.15
Net debt/EBITDA
-0.6
Margins
EBITDA margin
-484.2%
Gross margin
100%
Net margin
-527.2%
Operating margin
-495.5%
Efficiency
Return on assets
-177.8%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
-493%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PVCT stock price

How has the Provectus Biopharmaceuticals stock price performed over time
Intraday
19.52%
1 week
11.11%
1 month
96.34%
1 year
61.29%
YTD
38.5%
QTD
77.51%

Financial performance

How have Provectus Biopharmaceuticals's revenue and profit performed over time
Revenue
$601,437
Gross profit
$601,437
Operating income
-$2.98M
Net income
-$3.17M
Gross margin
100%
Net margin
-527.2%
The net margin has declined by 44% since the previous quarter and by 7% year-on-year
Provectus Biopharmaceuticals's operating margin has decreased by 43% QoQ and by 3% YoY
The gross profit has contracted by 29% from the previous quarter and by 27% YoY
The company's revenue fell by 29% QoQ and by 27% YoY

Growth

What is Provectus Biopharmaceuticals's growth rate over time

Valuation

What is Provectus Biopharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
104.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
107.53
Provectus Biopharmaceuticals's equity has decreased by 10% YoY and by 3% from the previous quarter
PVCT's P/S is 82% above its last 4 quarters average of 57.5
The company's revenue fell by 29% QoQ and by 27% YoY

Efficiency

How efficient is Provectus Biopharmaceuticals business performance
The ROS has contracted by 43% from the previous quarter and by 3.4% YoY
The company's return on assets fell by 18% YoY and by 7% QoQ

Dividends

What is PVCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PVCT.

Financial health

How did Provectus Biopharmaceuticals financials performed over time
Provectus Biopharmaceuticals's total assets is 82% lower than its total liabilities
PVCT's current ratio is down by 23% YoY and by 6% from the previous quarter
The quick ratio has contracted by 21% YoY
The debt is 142% greater than the equity
The debt is up by 16% year-on-year and by 11% since the previous quarter
Provectus Biopharmaceuticals's equity has decreased by 10% YoY and by 3% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.